Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM | INSM Price Prediction) and its lung disease franchise: Japan has more patients with MAC lung disease than the entire United States.
That came directly from CEO Will Lewis in a recent interview. “There are actually more patients in Japan that have this disease than there are in all of the United States. So it’s a very substantial market as well.”
That single line reframes the investment thesis considerably.
From 30,000 Patients to 200,000
ARIKAYCE, Insmed’s inhaled amikacin therapy, is currently approved to treat the refractory form of MAC lung disease, meaning patients who have already failed standard antibiotic therapy. That addressable market sits at around 30,000 patients.
The ENCORE Phase 3b trial, which announced positive results on March 23, 2026, meeting its primary and all secondary endpoints, tested ARIKAYCE as a first-line combination therapy alongside standard antibiotics. The results showed improvements in symptom scores, culture conversion (eradication of the underlying infection), and faster and more durable outcomes.
If the label expands to include first-line treatment, the total addressable market grows from 30,000 to more than 200,000 patients. That is not a modest step-up. It is a category transformation.
Insmed plans to file a supplemental NDA with the FDA in the second half of 2026, simultaneously filing in Japan. The full commercial impact of the label expansion is expected to materialize in 2027.
Japan Is Already Performing
The Japan opportunity is not hypothetical. The market is already producing. Japan delivered 40% growth in 2025 compared to 2024 and contributed more than a quarter of ARIKAYCE’s global revenues. In the quarters leading into that, Japan was growing even faster: 48.3% year-over-year in Q1 2025 and 45.3% in Q2 2025.
For context, U.S. ARIKAYCE growth during those same periods was 14.1% and 7.7% respectively. Japan is not a secondary market. It is running at a different speed entirely, and the patient population revelation from Lewis suggests the ceiling there is higher than most investors have modeled.
The Bigger Picture
Insmed now carries a dual-blockbuster structure. BRINSUPRI generated $144.6 million in its first full commercial quarter with full-year 2026 guidance of at least $1 billion. ARIKAYCE guidance for 2026 sits at $450 to $470 million. The analyst consensus price target is $213 against a current price of $143.98.
The ENCORE data removes the biggest overhang on ARIKAYCE’s long-term story. Add the Japan patient population disclosure, and the label expansion filing becomes a dual-market catalyst with a 2027 revenue ramp attached. The question analysts are now focused on is no longer whether ARIKAYCE can grow. It is how large a market Insmed is actually sitting on.
Top Gaining Stocks
Top Losing Stocks